Objective-Emerging evidence indicates that proinflammatory macrophage polarization imbalance plays a key role in atherosclerotic plaque progression and instability. The calcium-activated potassium channel KCa3.1 is critically involved in macrophage activation and function. However, the role of KCa3.1 in macrophage polarization is unknown. This study investigates the potential role of KCa3.1 in transcriptional regulation in macrophage polarization and its relationship to plaque instability. Approach and Results-Human monocytes were differentiated into macrophages using macrophage colony-stimulating factor. Macrophages were then polarized into proinflammatory M1 cells by interferon-γ and lipopolysaccharide and into alternative M2 macrophages by interleukin-4. A model for plaque instability was induced by combined partial ligation of the left renal artery and left common carotid artery in apolipoprotein E knockout mice. Significant upregulation of KCa3.1 expression was observed during the differentiation of human monocytes into macrophages. Blocking KCa3.1 significantly reduced the expression of proinflammatory genes during macrophages polarization. Further mechanistic studies indicated that blocking KCa3.1 inhibited macrophage differentiation toward the M1 phenotype by downregulating signal transducer and activator of transcription-1 phosphorylation. In animal models, KCa3.1 blockade therapy strikingly reduced the incidence of plaque rupture and luminal thrombus in carotid arteries, decreased the expression of markers associated with M1 macrophage polarization, and enhanced the expression of M2 markers within atherosclerotic lesions. 
A therosclerotic plaque instability, which results in plaque rupture and thromboembolism, is a primary cause of acute coronary syndrome and sudden cardiac death. 1 Emerging evidence indicates that myeloid lineage cells are the main cellular components within atherosclerotic lesions and play a critical role in the induction and progression of atherosclerotic inflammation, which contribute to plaque destabilization. 2 Macrophages within atherosclerotic plaque respond to stimuli from the microenvironment and exhibit functional heterogeneity and plasticity. [3] [4] [5] Macrophages can be broadly classified into proinflammatory (M1) or anti-inflammatory (M2) phenotypes on the basis of the cytokine environment that is created by 2 different classes of T helper cells (Th1 or Th2, respectively). 6 Classically activated M1 macrophages, induced by Th1 cytokines such as interferon (IFN)-γ, are the most prominent macrophages at sites of inflammation and are characterized by the expression of a broad spectrum of proinflammatory cytokines and chemokines. M1 macrophages promote atherosclerotic lesion development and complexity.
Alternatively activated M2 macrophages are primed by Th2 cytokines, such as interleukin (IL)-4, and promote tissue repair and healing. 7 Therefore, the stability of atherosclerotic plaques is highly dependent on the balance between these macrophage polarization states. 8 The molecules and mechanisms associated with plasticity and the polarized activation of macrophages may provide potential therapeutic targets for preventing plaque rupture.
The intermediate conductance calcium-activated potassium channel, known as KCa3.1, is part of signaling cascades that involve relatively global and prolonged calcium elevation during cellular activation, proliferation, cytokine secretion, and volume regulation in many immune cells, including T cells, B cells, microglia, and macrophages. Therefore, KCa3.1 is an attractive pharmacological target for use in immunotherapy. [9] [10] [11] KCa3.1 gating is voltage independent and only requires a small increase in intracellular calcium. Intracellular calcium binds to calmodulin molecules that are constitutively associated with the channel protein and induce channel opening, which results in K + efflux that maintains a negative membrane potential. Thus, the initial influx of Ca 2+ feeds forward, thereby, preserving the negative V m (membrane voltage) required for sustained Ca 2+ influx. 12 The Ca 2+ influx leads to an increase in cytosolic Ca 2+ concentration, which is necessary for the translocation of nuclear factors to the nucleus and the initiation of new transcription.
Particularly, in macrophages, KCa3.1 has been shown to be involved in activation, migration, proliferation, and respiratory bursting, indicating that KCa3.1 suppression might be helpful in some macrophage-related disorders, such as asthma, multiple sclerosis, stroke, and so forth. [13] [14] [15] Previous evidence has demonstrated a role for KCa3.1 in atherosclerosis. In mouse models, pharmacological inhibition of KCa3.1 by the selective blocker TRAM-34 attenuates atherosclerotic lesion formation and may provide a novel approach for the prevention and treatment of atherosclerosis. 16 However, in advanced atherosclerotic lesions, the role of KCa3.1 in the pathogenesis of plaque instability and its underlying mechanisms are unknown. A recent study reported that IL-4 stimulation increases KCa3.1 current in microglia, 17 which suggests that KCa3.1 may be involved in the polarization of macrophages and atherosclerotic plaque disruption. In this study, we pharmacologically modulated KCa3.1 activity and examined how this altered macrophage phenotype and determined its effect on plaque stability.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Cell Culture and Differentiation
Human monocytes were isolated from peripheral blood of 12 healthy volunteers and cultured in RPMI (Roswell Park Memorial Institute) medium supplemented with 10% fetal bovine plasma. We obtained informed consent from all subjects and a license from the ethical committee. Macrophage differentiation of human monocytes was induced by treatment with 100 ng/mL macrophage colony-stimulating factor. Human monocytes-derived macrophages were treated with 100 ng/mL IFN-γ and 10 ng/mL lipopolysaccharide (LPS) for M1 differentiation. M2 polarization was induced by incubating macrophages with 15 ng/mL IL-4.
Animals and Treatment
ApoE-deficient (ApoE −/− ) male mice on a C57BL/6 background (n=18) were obtained from the Jackson Laboratory (Bar Harbor, ME) at the age of 7 weeks and were maintained in 12-hour light/ dark cycles. The mice were allowed to acclimate for a week prior to the study and were fed with a high-fat diet (1.25% cholesterol and 21% fat; 42% kcal as fat) during the experiment. Unstable carotid atherosclerotic lesions were induced by combined partial ligation of the left renal artery and left internal and external carotid artery with perivascular collars. 18 Six weeks after surgery, all mice were randomly assigned to either an interventional or a control group. Mice in the interventional group were treated with daily subcutaneous injection of TRAM-34 (120 mg/kg) for 3 weeks, whereas mice in the control group were injected with vehicle (Miglyol 812). At the end of the experiments, the animals were deeply anesthetized and euthanized with an intraperitoneal injection of pentobarbital sodium (50 mg/kg). Blood was drawn from the inferior vena cava, and the carotid arteries were then harvested after in situ perfusion with heparin/saline via the left ventricle. All animal procedures were conducted in accordance with the guidelines on animal care and use of Fudan University.
Results

KCa3.1 Expression Profile in Macrophages
KCa3.1 protein expression during macrophage differentiation and polarization was assessed by immunofluorescence and Western blotting ( Figure 1A through 1C Whole-cell patch-clamp experiments corroborated the protein expression data. KCa3.1 current was elicited with voltage ramps from −120 to 40 mV for 200 ms. KCa3.1 conductance was quantified from the slope of the current voltage relationship at −80 mV. Although KCa3.1 current was barely detectable in unstimulated human monocytes, the amplitude of the KCa3.1 current increased after macrophage colonystimulating factor stimulation. In agreement with the immunofluorescence and Western blot analysis, both M1 and M2 macrophages showed significantly increased channel current amplitudes and conductance after polarization, though the increased trend was more pronounced in M1 macrophages ( Figure 1D and 1E ).
KCa3.1 Blockade Impairs Proinflammatory Genes Expression During Macrophage Polarization
To determine whether KCa3.1 channels are involved in the polarization process, macrophages were also treated with TRAM-34 during IFN-γ and LPS or IL-4 stimulation. Surface marker expression and cytokine profiles during macrophages polarization were evaluated by flow cytometry and real-time polymerase chain reaction. M1 macrophages are characterized by higher cell surface marker levels, including CD80 and CD197. M2 macrophages differed from M1 in that they expressed higher levels of CD163 and CD206. Our results showed that IFN-γ plus LPS significantly increased the expression of CD80 and CD197 with no effect on CD163 and CD206, whereas IL-4 only significantly upregulated CD163 and CD206 levels. We also revealed that coculture with TRAM-34 significantly reduced IFN-γ and LPS-induced CD80 and CD197 expression. In contrast, TRAM-34 treatment only slightly decreased IL-4-induced CD163 and CD206 expression, and there was no statistically significant difference ( Figure 2A ; Figure I in the online-only Data Supplement). Consistent with these observations, blocking KCa3.1 significantly attenuated proinflammatory cytokine and chemokine mRNA expression in M1 macrophages, including CCR7, tumor necrosis factor-α, and IL-12p35. However, M2 macrophage markers, such as CXCR4, CD206, and IL-10, were unaltered or only marginally decreased with TRAM-34 cotreatment ( Figure 2B ). Moreover, similar results were obtained in KCa3.1 siRNA-treated THP-1 cells, which displayed similar KCa3.1 channel expression patterns during differentiation and polarization ( Figure II in the online-only Data Supplement). These in vitro data suggest that KCa3.1 channels play a more important role in the expression of proinflammatory genes during macrophage polarization, and blocking KCa3.1 channels with TRAM-34 results in a reduced M1 macrophage function. The receptors for IFN-γ (IFN-γ receptor-1), LPS (Toll-like receptor 4), and IL-4 (IL-4 receptor-α) on macrophages were also assessed. There were no differences in the expression of these receptors between the macrophages treated with or without TRAM-34, which excludes the possibility that low proinflammatory gene expression in TRAM-34-treated macrophages is because of IFN-γ receptor-1 or Toll-like receptor 4 expression defects ( Figure 2B ).
KCa3.1 Regulates Proinflammatory Genes During Macrophage Polarization Through the Signal Transducer and Activator of Transcription Pathway
Signal transducer and activator of transcription (STAT) proteins have been reported to be of critical importance for determining macrophage phenotypes in well-established signaling pathways regulating macrophage polarization. 19, 20 During M1 polarization, STAT-1 becomes phosphorylated and promotes M1 gene program transcription. Conversely, the exposure of macrophages to IL-4 activates the STAT-3/STAT-6 pathway and promotes the transcription of M2 phenotype-associated genes, while the activity of STAT-1 is significantly decreased. Therefore, the balance between STAT-1 and STAT-3/STAT-6 seems to dictate the fate of macrophage polarization during the immune response. In this experiment, because of the limited availability of human monocytes, we used THP-1 cells to investigate the effects of KCa3.1 blockade on STAT phosphorylation/activation. Blocking KCa3.1 with TRAM-34 significantly decreased IFN-γ and LPS-induced STAT-1 phosphorylation. Mechanistically, KCa3.1 inhibition suppressed IFN-γ and LPSinduced proinflammatory gene expression during M1 polarization by inhibiting STAT-1 activation. In contrast, TRAM-34 cotreatment did not change STAT-3/STAT-6 phosphorylation during IL-4 stimulation, which may explain why blocking KCa3.1 had few effects on M2 polarization in vitro ( Figure 2C ).
Blocking KCa3.1 Channels Promotes Plaque Stability and Reduces the Risk of Rupture
To determine the role of KCa3.1 channels in plaque stability, a murine model mimicking human plaque rupture was generated by combined partial ligation of the left renal artery and the left internal and external carotid arteries in 8-week-old ApoE −/− mice. TRAM-34 dissolved in Miglyol 812 was administered once daily (120 mg/kg, SC) for 3 weeks beginning at 6 weeks after surgery. High-resolution microultrasound imaging was conducted every 3 weeks to assess the progression of the carotid plaques. B-mode and pulse-wave Doppler were performed to evaluate the degree of stenosis and the hemodynamic status in the carotid artery ( Figure 3A and 3B) . At the beginning, no plaque was detected in the left common carotid artery. Six weeks later, atherosclerotic plaques were clearly visualized by microultrasound imaging on the left common carotid arteries. No significant changes were observed in the ultrasound-measured parameters between the 2 groups at baseline. At the end of the experiment, TRAM-34 treatment significantly lowered the ultrasound-measured plaque intimamedial thickness ( Figure 3C ). Blood pressure was also measured using the tail-cuff method at each time point before microultrasound imaging. TRAM-34 treatment did not affect the hypertensive response to renal artery ligation (Table I in the online-only Data Supplement).
After the ultrasound detection at 9 weeks after surgery, the mice were euthanized, and the left common carotid arteries were isolated after pressure perfusion. Compared with the vehicle-treated group, the animals that received TRAM-34 injection showed an obviously lower incidence of fresh left common carotid arterial lumen thrombus associated with severe plaque burden (1/9 versus 6/9; P=0.016; Figure 4A ). Plaque composition was assessed with special stains and immunocytochemistry coupled with quantitative image analysis ( Figure 4B and 4C each group) . B, Real-time polymerase chain reaction was performed to further evaluate the transcript expression of genes related to M1 and M2 macrophage polarization (n=5-6 in each group). C, Western blotting was conducted on cell lysates with antibodies for P-STAT1, P-STAT3, and P-STAT6; total STAT1, STAT3, and STAT6; and GAPDH. The relative densities for the phosphorylated STAT compared with total STAT are shown as histograms (n=4 in each group). Statistical significance values (P) are indicated. MFI indicates mean fluorescence intensity; and STAT, signal transducer and activator of transcription. Figure 4D and 4E).
As reported, KCa3.1 channels play an important role in the regulation of inflammatory cytokine expression. To investigate this further, proinflammatory cytokine plasma levels were assessed ( Figure 4F ). TRAM-34-treated mice exhibited a significant reduction in plasma proinflammatory cytokine levels, including IL-2, IL-6, tumor necrosis factor-α, and monocyte chemoattractant protein, and increased the plasma levels of the anti-inflammatory cytokine IL-10. TRAM-34 treatment did not affect plasma IL-1β and macrophage inflammatory protein-1α levels. We also analyzed the plasma lipid profiles in these mice. Lipids were highly elevated in ApoE −/− mice fed a high-fat diet. However, there were no significant differences in glucose, triglycerides, and total cholesterol between the vehicle-and TRAM-34-treated groups (Table I in the online-only Data Supplement). 
TRAM-34 Treatment Suppresses M1 and Promotes M2 Macrophage Polarization Within Atherosclerotic Lesions
Recent advances indicate that the relative abundance of macrophage phenotypes, rather than the absolute number, is more relevant to atherosclerotic plaque phenotype and lesion progression. 5 To determine whether the enhanced plaque stability in TRAM-34-treated animals correlated with a decreased M1:M2 macrophage ratio, we performed double immunofluorescence experiments in carotid crosssections to analyze macrophage polarization in atherosclerotic lesions. These studies showed that Mac3 + macrophages from carotid lesions in TRAM-34-treated mice exhibited decreased expression for M1 markers, including fatty acidbinding protein-4 and CD36, and increased expression for M2 markers, including arginasae-1 and peroxisome proliferator-activated receptor γ coactivator-1 ( Figure 5A , 5B, and 5D). Moreover, the expression of KCa3.1 on Mac3 + macrophages within the plaque was markedly suppressed in TRAM-34-treated mice, which also indicated the effectiveness of the treatment ( Figure 5C and 5D ).
Discussion
The calcium-activated K + channel KCa3.1 plays an important role in several macrophage functions, including respiratory burst, migration, and macrophage-mediated pathogen killing in vitro and in vivo. Here, we extend these findings and present the first evidence suggesting that KCa3.1 channels also play a key role in regulating proinflammatory gene expression during macrophage polarization. Based on these observations, the KCa3.1 blockers likely reduce inflammation and stabilize atherosclerotic plaques. Here, we provide proof-of-concept evidence that blocking KCa3.1 with TRAM-34 reduces atherosclerotic lesion burden and enhances plaque stability with a concomitant decrease in proinflammatory markers and an increase in anti-inflammatory markers in macrophage population within atherosclerotic lesions. Altogether, our results highlight a critical role for KCa3.1 channels in determining Continued. surface area, plaque collagen, and lipid content (n=3-6 in each group). Plaque stability was assessed by the collagen to lipid ratio. D, Representative photographs of sections of the carotid artery that were immunostained with either the smooth muscle cell-specific marker smooth muscle actin (α-SMA), the macrophage-specific marker Mac3, or the T cell-specific marker CD3. E, Quantification of α-SMA, Mac3, and CD3 in carotid lesions. Plaque stability was assessed with the forming α-SMA to Mac-3 ratio (n=6 in each group). F, Plasma cytokine levels for interleukin (IL)-1β, IL-2, IL-6, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MIP)-1α, MCP-1, and IL-10 (n=9 in each group). Statistical significance values (P) are indicated.
proinflammatory genes expression in macrophage polarization and atherosclerotic plaque instability.
Monocytes and their descendant macrophages are consistently found in atherosclerotic lesions and contribute to plaque growth and activity. During the early stages of atherosclerosis, circulating monocytes are involved in the initiation and progression of the disease by infiltrating the vessel wall and becoming lesional macrophages. 21, 22 KCa3.1 expression is high in macrophages that infiltrate atherosclerotic plaques but not in monocytes. Therefore, treating ApoE −/− mice with TRAM-34 resulted in reduced atherosclerosis, which was associated with decreased recruitment of monocytes into the vascular wall. 16 Our results also confirmed that KCa3.1 expression was significantly upregulated during the differentiation of human monocytes into macrophages. However, during the later stages of plaque development, local proliferation accounted for ≈90% of macrophage accumulation in established disease. 23 Moreover, the results from studies on human atherosclerotic plaques have demonstrated that the relative proportion of macrophage subsets within plaques is a better predictor of plaque compositional phenotype and related stability than the total number of macrophages. Changing the composition of resident macrophages during advanced atherosclerosis stages would affect plaque instability; therefore, the identification of agents that are responsible for M1 or M2 polarization is of great importance.
As mentioned earlier, the KCa3.1 channel is pivotal in regulating multiple macrophages functions. Moreover, recent studies have indicated that expression of KCCN4, the gene that encodes the KCa3.1 channel, is upregulated in IL-4-treated human macrophages. 17, 24 However, the expression pattern of KCa3.1 channels and their role in modulating the balance of macrophage phenotypes are still not well defined. Using the whole-cell patch clamp recording method and Western blot assays, we demonstrated increased KCa3.1 levels in IFN-γ and LPS-treated macrophages, as well as in IL-4-treated macrophages, though the increase was significantly larger in the IFN-γ and LPS-induced M1 macrophages. These results support the potential importance for KCa3.1 channels during macrophage polarization. In the present study, we showed that specific gene silencing or blocking KCa3.1 dramatically inhibited the expression of proinflammatory markers and cytokines during macrophages polarization in vitro.
In agreement with our in vitro studies, in vivo data showed a reduced number of M1 proinflammatory macrophages in advanced plaques found in TRAM-34-treated mice. It is interesting that blocking KCa3.1 significantly increased the expression of M2 macrophage markers in atherosclerotic lesions, which is different from the in vitro results. Indeed, depending on environmental signals, macrophages can display a spectrum of activation states in vivo. A continuum of pro-and anti-inflammatory macrophages, with extreme polarization phenotypes M1 and M2 macrophages, can be found in atherosclerotic lesions. 3 The local microenvironment present in the atherosclerotic lesion, which predominantly determines the polarization of the plaque macrophages, is more complex than typically described by the M1/M2 paradigm. 25 Therefore, the local cytokine milieu can determine macrophage polarization and plasticity. In our study, TRAM-34 treatment promoted anti-inflammatory and inhibited proinflammatory cytokine expression, which may explain the shift in the macrophage spectrum toward an M2 phenotype in vivo. Consequently, increased collagen/lipid and smooth muscle cell/macrophage ratios were observed in TRAM-34-treated mice, which are suggestive of more stable and less complex lesions. 26 Notably, blood pressure, plasma cholesterol, and triglycerides profiles in the vehicle-treated mice versus the TRAM-34-treated mice were not significantly different.
In addition to macrophages, KCa3.1 channels have been demonstrated to express on VSMCs, T cells, and endothelial cells, all of which are also involved in the pathogenesis of atherosclerosis. 11, 16 It has been reported that long-term blocking KCa3.1 therapy with TRAM-34 strikingly inhibited VSMCs proliferation and T cells infiltration and reduced atherosclerosis in ApoE −/− mouse. 16 In our experiments, however, TRAM-34 therapy was administered for 3 weeks and did not change the proportion of T cells and even increased the VSMC content. In the early stages of atherosclerosis, most of the T cells present in atherosclerotic plaques are naive and central memory T cells that express high numbers of KCa3.1 channels; however, in more advanced stages, they convert to effector memory T cells and contribute to the destabilization of atherosclerotic lesions. 16, 27 Different from naive and central memory T cells, Kv1.3 is the functionally dominating K + channel in effector memory T cells. 27 Therefore, in vivo therapy with TRAM-34 during the advance stages of atherosclerosis did not decrease CD3 + T cell in lesions. Similarly, there is also a phenotypic switching of VSMCs during the progression of atherosclerosis. 28 Increased VSMCs proliferation is observed during early atherogenesis and promotes plaque formation. In contrast, VSMCs derived from advanced atherosclerotic plaques undergo reduced proliferation, and VSMC apoptosis seems to be a critical event in plaque rupture. It has been suggested that VSMCs apoptosis is potentially induced by macrophages via death ligand/death receptor interactions and tumor necrosis factor-α secretion. 28, 29 In our study, the mechanism underlying the increased VSMCs content in TRAM-34-treated mice is possibly an indirect effect on macrophages that induce VSMCs apoptosis in the lesion. However, we cannot completely exclude that it is not a direct effect of TRAM-34 treatment on VSMCs in advanced lesions. In endothelial cells, the blocking KCa3.1 channels acts as a double-edge sword. On the one hand, KCa3.1 inhibition can cause endothelial dysfunction and, thereby, contribute to vascular diseases 30 ; in contrast, KCa3.1 channels are involved in endothelial cell proliferation and angiogenesis, which contribute to the progression of advanced atherosclerotic plaques. 31 The inhibition of angiogenesis in advanced plaques may contribute to TRAM-34's therapeutic effect. Additionally, given the role of TRAM-34 treatment in systemic immunosuppression, 11 further studies are needed to clarify the potential role of KCa3.1 in systemic inflammation that can contribute to plaque instability.
Regarding the signaling pathways by which KCa3.1 regulates macrophage polarization, recent studies have determined that there is a balance between the STAT-1 and STAT-3/ STAT-6 pathways and macrophage polarization. Exposing macrophages to M1 phenotype inducers, such as IFN-γ and LPS, leads to the phosphorylation of STAT-1, which promotes the transcription of the M1 gene program. 32 In contrast, IL-4 stimulation causes the phosphorylation of STAT-6 and the transcription of M2 phenotype-associated genes. 33 The KCa3.1 potassium channel has been demonstrated to impact the function of macrophages by regulating intracellular Ca 2+ homeostasis. 9 Furthermore, a recent study indicated that intracellular Ca2 + overloading triggers greater macrophage production of inflammatory mediators and promotes classically activated macrophage M1 polarization. 34 In the present study, we found that decreasing STAT-1 phosphorylation underscores the role of blocking KCa3.1 in inhibiting proinflammatory genes expression during macrophage polarization and attenuating plaque instability. However, further study is needed to understand the mechanisms that underlie the interplay between KCa3.1 and JAK/STAT signaling in detail.
As previously mentioned, several reports suggest that blocking KCa3.1 has beneficial effects on chronic neurodegenerative disorders, ulcerative colitis, obliterative airway disease, neuroinflammation associated with ischemia/reperfusion stroke, and resistance to oxidative stress. 15, [35] [36] [37] These pathological processes all involve the activation of an acute or chronic inflammatory response. Therefore, the potential of blocking KCa3.1 to change the balance in M1 and M2 macrophages and promote alternative, anti-inflammatory macrophage phenotypes presents another possible mechanism that contributes to its protective effects in these diverse pathological conditions.
